Track topics on Twitter Track topics that are important to you
BOULDER, CO--(Marketwired - August 10, 2015) - SomaLogic, Inc., announced today that Otsuka Pharmaceutical Co., Ltd. has extended its initial collaboration agreement with SomaLogic to continue the development of several SOMAmer®
therapeutics. Specific projects and financial terms in the extended agreement were not disclosed.
"SOMAmer molecules are a promising new class of drug entities, and we are excited to continue our work with SomaLogic to fully realize that promise," said Takayuki Shiratsuchi, Operating Officer and General Manager of Basic Research at Otsuka Pharmaceutical. "We are optimistic that extending this collaboration will help accelerate several of our ongoing therapeutics discovery and development efforts."
SomaLogic is the recognized leader in the development and application of advanced aptamer technologies. The company has designed its proprietary SOMAmer (Slow Off-rate Modified Aptamer) reagents to combine the wide target range of antibodies with the consistency and reproducibility of traditional aptamers. The chemical addition of "protein-like" side chains to the nucleic acid bases that comprise a SOMAmer molecule results in the ability to discover molecules that bind specifically and tightly to virtually any targeted protein. These properties allow SOMAmer molecules to be used in virtually any laboratory or clinical application that currently uses monoclonal antibodies, including therapeutics. For example, SOMAmer molecules have been demonstrated to be potent inhibitors of specific targeted proteins. This property, along with other unique characteristics, makes SOMAmer candidates attractive for novel therapeutic discovery and development.
"We are delighted that our Otsuka colleagues see the value of our technology, and have chosen to extend their productive collaboration with us," said Byron Hewett, CEO of SomaLogic. "The projects we are continuing to develop with them hold great potential for bringing novel therapeutics to the clinic for several unmet clinical needs."
SomaLogic is transforming healthcare by applying our proprietary protein-measurement technology to the development of new diagnostic tests that deliver a higher quality of life by detecting diseases at their earliest stages and monitoring general wellness. Our ultimate goal is the "Wellness Chip," a single cost-effective and reliable blood test for multiple diseases and conditions that will enable healthcare providers to precisely monitor each individual's state of health and wellness in real time.
Our technology also has multiple potential applications in both life sciences and therapeutics, and it is now available to the entire biomedical scientific community for their own research needs.
For more information, visit www.somalogic.com.
Otsuka creates pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka, headquartered in Japan, welcomes you to visit its global website at https://www.otsuka.co.jp/en.Fintan R. Steele, Ph.D. Executive Director of Corporate Communications +1 720-214-3080 - P +1 617-816-9834 - CNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...